Holistic Financial Partners Sells 1,751 Shares of AstraZeneca PLC (NASDAQ:AZN)

Holistic Financial Partners cut its stake in AstraZeneca PLC (NASDAQ:AZN) by 30.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,080 shares of the company’s stock after selling 1,751 shares during the period. Holistic Financial Partners’ holdings in AstraZeneca were worth $318,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Claro Advisors LLC bought a new stake in AstraZeneca in the 3rd quarter valued at approximately $233,000. Atlanta Consulting Group Advisors LLC bought a new position in shares of AstraZeneca during the 3rd quarter worth approximately $204,000. Natixis Advisors LLC lifted its position in shares of AstraZeneca by 6.4% in the third quarter. Natixis Advisors LLC now owns 1,960,815 shares of the company’s stock worth $152,767,000 after purchasing an additional 117,162 shares in the last quarter. Koa Wealth Management LLC boosted its holdings in AstraZeneca by 35.3% during the third quarter. Koa Wealth Management LLC now owns 25,678 shares of the company’s stock worth $2,001,000 after purchasing an additional 6,698 shares during the last quarter. Finally, CIBC Asset Management Inc boosted its holdings in AstraZeneca by 2.3% during the third quarter. CIBC Asset Management Inc now owns 238,268 shares of the company’s stock worth $18,563,000 after purchasing an additional 5,269 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of AZN stock opened at $63.23 on Monday. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68. The company has a market capitalization of $196.05 billion, a price-to-earnings ratio of 30.25, a PEG ratio of 1.17 and a beta of 0.47. The company has a 50-day simple moving average of $75.03 and a 200 day simple moving average of $78.23. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.87 earnings per share. On average, sell-side analysts predict that AstraZeneca PLC will post 4.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. TD Cowen boosted their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Finally, Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, AstraZeneca currently has an average rating of “Buy” and a consensus price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.